Jazz Pharmaceuticals (NASDAQ:JAZZ) Director Sells $662,143.37 in Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Director Rick Winningham sold 2,741 shares of the business’s stock in a transaction that occurred on Friday, May 22nd. The stock was sold at an average price of $241.57, for a total value of $662,143.37. Following the completion of the sale, the director owned 9,567 shares of the company’s stock, valued at approximately $2,311,100.19. This trade represents a 22.27% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Jazz Pharmaceuticals Stock Performance

JAZZ traded up $0.15 on Wednesday, hitting $237.56. The company had a trading volume of 615,345 shares, compared to its average volume of 991,333. The company’s fifty day moving average price is $204.80 and its 200 day moving average price is $181.71. Jazz Pharmaceuticals PLC has a 1-year low of $105.00 and a 1-year high of $243.32. The company has a debt-to-equity ratio of 0.95, a current ratio of 2.04 and a quick ratio of 1.85. The stock has a market cap of $14.90 billion, a price-to-earnings ratio of -11,872.06, a price-to-earnings-growth ratio of 0.43 and a beta of 0.27.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share for the quarter. Jazz Pharmaceuticals had a return on equity of 14.56% and a net margin of 0.66%.The firm had revenue of $1.07 billion during the quarter. Equities analysts predict that Jazz Pharmaceuticals PLC will post 20.75 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

JAZZ has been the topic of several recent analyst reports. Leerink Partners lifted their price target on Jazz Pharmaceuticals from $215.00 to $225.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 22nd. Piper Sandler lifted their price target on Jazz Pharmaceuticals from $232.00 to $301.00 and gave the stock an “overweight” rating in a research report on Friday, May 22nd. UBS Group raised Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $188.00 to $307.00 in a research report on Tuesday, May 19th. Wells Fargo & Company lifted their price target on Jazz Pharmaceuticals from $250.00 to $265.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 6th. Finally, Bank of America lifted their price target on Jazz Pharmaceuticals from $263.00 to $275.00 and gave the stock a “buy” rating in a research report on Wednesday, February 25th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, Jazz Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $242.65.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Glenmede Trust Co. NA increased its position in shares of Jazz Pharmaceuticals by 1.9% during the first quarter. Glenmede Trust Co. NA now owns 7,819 shares of the specialty pharmaceutical company’s stock valued at $1,478,000 after purchasing an additional 146 shares during the period. Bank of America Corp DE increased its position in shares of Jazz Pharmaceuticals by 10.9% during the first quarter. Bank of America Corp DE now owns 1,014,800 shares of the specialty pharmaceutical company’s stock valued at $191,848,000 after purchasing an additional 99,656 shares during the period. Tri Locum Partners LP bought a new stake in shares of Jazz Pharmaceuticals during the first quarter valued at approximately $29,995,000. Amundi increased its position in shares of Jazz Pharmaceuticals by 2,445.3% during the first quarter. Amundi now owns 55,640 shares of the specialty pharmaceutical company’s stock valued at $10,519,000 after purchasing an additional 53,454 shares during the period. Finally, EverSource Wealth Advisors LLC increased its position in shares of Jazz Pharmaceuticals by 94.6% during the first quarter. EverSource Wealth Advisors LLC now owns 1,520 shares of the specialty pharmaceutical company’s stock valued at $287,000 after purchasing an additional 739 shares during the period. 89.14% of the stock is owned by institutional investors.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.